In a recent study, researchers have discovered a new mechanism involved in the expression of down syndrome, one of the main causes of intellectual disability and congenital heart defects in children.
The study was conducted by researchers at CHU Sainte-Justine and Universite de Montreal.
The study's findings were published in the journal Current Biology.
Down syndrome (SD), also called trisomy 21 syndrome, is a genetic condition that affects approximately one in every 800 children born in Canada. Among these individuals, many genes are expressed abnormally at the same time, making it difficult to determine which genes contribute to which differences.
Prof Jannic Boehm's research team focused on RCAN1, a gene that is overexpressed in the brains of fetuses with Down syndrome. The team's work provides insights into how the gene influences the way the condition manifests itself.
The human brain is made up of hundreds of billions of cells known as neurons. They communicate with each other through synapses, which are small gaps between neurons. The ability of synapses to strengthen or weaken over time is known as 'synaptic plasticity.' It's an important biological phenomenon because it's essential for memory and learning.
"There are two kinds of synaptic plasticity: long-term potentiation, which strengthens synapses and improves the interaction between neurons, and long-term depression, which weakens synapses," said Boehm, a professor at Universite de Montreal and researcher at CHU Sainte-Justine.
"We already knew that synaptic plasticity is influenced by certain proteins," added Anthony Dudilot, one of the study's first authors. "For example, calcineurin is inhibited when long-term potentiation is induced, but it's activated when long-term depression begins. But the molecular mechanism underlying calcineurin regulation was less clear."
The research team found that the various signalling pathways that trigger synaptic potentiation or depression converge on RCAN1. They also determined that the gene regulates calcineurin activity by inhibiting or facilitating it.
Given its dual role as an inhibitor or facilitator, the researchers deduced that RCAN1 works as a "switch" that regulates synaptic plasticity, thereby affecting learning and memory.
"This is the first time that the molecular mechanism for calcineurin regulation in bidirectional synaptic plasticity has been determined," said Boehm.
"This breakthrough explains how overexpression of the RCAN1 gene could cause intellectual disabilities in individuals with Down syndrome. It also opens up the possibility of developing innovative treatments for affected patients.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
